Swiss biopharmaceuticals company Biopartners Holdings has terminated its supply agreement with The Medical House, the firm has announced.
In February 2005, The Medical House signed a 10-year supply agreement with Biopartners GmbH for the license and supply of The Medical House’s GH1 reusable, spring powered, needle-free delivery system for the delivery of Biopartners’ human growth hormone product Valtropin (somatropin injection).
In 2006 Biopartners initiated a comparative bioavailability/bioequivalence study in volunteers to assess Valtropin delivered by The Medical House’s GH1.
Biopartners concluded that The Medical House has never been able to supply the GH1 devices needed to perform this clinical study, so Biopartners terminated the collaboration.
Biopartners CEO Jean-Noël Treilles said: “Having received EMEA approval in April 2006, we had planned to launch Valtropin at the end of that year.
“However, with the GH1 device not functioning correctly, we have had to end our agreement with The Medical House in order to seek a suitable and robust alternative delivery system.”